In its latest quarterly report, Abbott Laboratories reported a mixed performance across its core businesses. The Medical Devices division drove robust momentum, led by continuous glucose monitoring systems, delivering double-digit revenue growth. This strength offset an 8–9% year-over-year decline in the Nutrition segment and a pullback in COVID-19 diagnostics revenue. Management reaffirmed its full-year outlook, forecasting 7% aggregate sales growth and 10% EPS growth for 2025, underpinned by new product launches in diabetes care, a gradual normalization in Nutrition pricing, and ongoing cost-efficiency initiatives across all divisions.

A panel of 22 brokerages maintains a constructive stance on Abbott, with 17 issuing Buy recommendations, three Hold, and two Strong Buy. Over the past quarter, five major firms trimmed their 12-month price targets—Citigroup reduced its target from 155 to 140, Sanford Bernstein from 154 to 125, RBC from 147 to 135, BTIG from 145 to 140, and Goldman Sachs from 152 to 140—while preserving Outperform or Buy ratings. The consensus target stands near 141, reflecting confidence in the company’s long-term growth drivers despite near-term headwinds in Nutrition and Diagnostics.

Abbott’s India unit is under investigation for the distribution of Phensedyl, a codeine-based cough syrup, following reports that 22 million bottles—valued at approximately $55 million—were supplied to wholesalers in Uttar Pradesh between April 2024 and March 2025. Although Abbott halted production of the drug in December 2024, regulators recovered 30,000 bottles hidden in rice sacks, suggesting illegal diversion through unofficial channels. State officials visited the Himachal Pradesh manufacturing site on January 14 and obtained detailed production and distribution records, though Abbott has not been formally accused of wrongdoing.